Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.54 |
| ▸ | DRD1 | P21728 | 11/20 | 0.53 |
| ▸ | DRD2 | P14416 | 10/20 | 0.53 |
| ▸ | DRD5 | P21918 | 9/20 | 0.53 |
| ▸ | DRD3 | P35462 | 8/20 | 0.53 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 6/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | PRKCI | P41743 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30199197 | 0.92 | CYP2A6 (0.54) | CYP2A6DRD1DRD2DRD5DRD3 | |
| SCHEMBL266616 | 0.92 | CYP2A6 (0.54) | CYP2A6DRD1DRD2DRD5DRD3 | |
| SCHEMBL13590991 | 0.85 | CYP1A2 (0.50) | DRD1DRD2DRD5DRD3PBRM1 | |
| SCHEMBL8408108 | 0.79 | — | — | |
| SCHEMBL588130 | 0.79 | CYP2A6 (0.54) | CYP2A6CYP1A2CYP3A4CYP2C9CYP11B1 | |
| Ammonia Solution, Strong SCHEMBL21632258 | 0.77 | DRD2 (0.54) | DRD1DRD2DRD5DRD3PBRM1 | |
| SCHEMBL6903685 | 0.77 | DRD1 (0.76) | CYP2A6DRD1DRD2DRD5DRD3 | |
| SCHEMBL1701852 | 0.75 | CYP2A6 (0.54) | CYP2A6CYP1A2CYP3A4CYP2C9CYP11B1 | |
| SCHEMBL12152856 | 0.75 | CYP2A6 (0.54) | CYP2A6PBRM1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL354022 | 0.75 | CYP2A6 (0.54) | CYP2A6CYP1A2CYP3A4CYP2C9CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117586289-A | Preparation method of 2- (6- (benzyloxy) -3, 4-dihydronaphthalene-2-yl) -4, 5-5-tetramethyl-1, 3, 2-dioxaborane | 四川新迪生物制药有限公司 | 2024-02-23 | — | — | CN | claimed |
| CN-116969848-A | Preparation method of intermediate of drug for treating advanced breast cancer | 北京康立生医药技术开发有限公司 | 2023-10-31 | — | — | CN | claimed |
| CN-122059824-A | Synthesis method of ilalastyl chiral intermediate | 上海格苓凯生物科技有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20260035339-A1 | TETRAHYDRONAPHTHALENE DERIVATIVE | ATRANSEN PHARMA LTD (JP) | 2026-02-05 | — | — | US | disclosed |
| CN-116969848-B | Preparation method of intermediate of drug for treating advanced breast cancer | 北京康立生医药技术开发有限公司 | 2025-12-12 | — | — | CN | disclosed |
| CN-119569588-A | Preparation method and intermediate of ilast hydrochloride | 杭州诺澳生物医药科技有限公司 | 2025-03-07 | — | — | CN | disclosed |
| EP-4501906-A1 | TETRAHYDRONAPHTHALENE DERIVATIVE | Atransen Pharma Ltd. (JP) | 2025-02-05 | — | — | EP | disclosed |
| CN-119100936-A | In the ilast group Synthesis method of intermediate | 杭州诺澳生物医药科技有限公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-118974007-A | Tetrahydronaphthalene derivatives | 阿创森制药股份有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118702588-A | Preparation method of ilast and intermediate thereof | 重庆华邦胜凯制药有限公司 | 2024-09-27 | — | — | CN | disclosed |
| WO-2024175615-A1 | DIHYDRONAPTHALENE DERIVATIVES | MERCK PATENT GMBH (DE) | 2024-08-29 | — | — | WO | disclosed |
| CN-1756746-A | 6-substituted nicotinamide derivatives as opioid receptor antagonists | LILLY CO ELI (US) | 2006-04-05 | — | — | CN | disclosed |
| EP-1613597-A1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | Eli Lilly and Company (US) | 2006-01-11 | — | — | EP | disclosed |
| EP-1569645-A2 | METHOD OF USING AMINOCYANOPYRIDINE COMPOUNDS AS MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITORS | Pharmacia Corporation (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1569932-A1 | AMINOCYANOPYRIDINE INHIBITORS OF MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | Pharmacia Corporation (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004080968-A1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2004-09-23 | — | — | WO | disclosed |
| US-20040142978-A1 | Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION (US) | 2004-07-22 | — | — | US | disclosed |
| WO-2004055015-A1 | AMINOCYANOPYRIDINE INHIBITORS OF MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | PHARMACIA CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| WO-2004054505-A2 | METHOD OF USING AMINOCYANOPYRIDINE COMPOUNDS AS MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITORS | PHARMACIA CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| US-20040127519-A1 | Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127519-A1 | Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors | MAPKAPK2, MAP2K2, MAP3K2 | CYP2A6 2913/4885DRD1 4132/4885DRD2 3188/4885 |
| US-20040142978-A1 | Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2 | MAP4K2, MAP3K20, MAPKAPK2 | CYP2A6 3903/4885DRD1 4330/4885DRD2 3273/4885 |
| US-20260035339-A1 | TETRAHYDRONAPHTHALENE DERIVATIVE | LATS1, LATS2, BCAT1 | CYP2A6 1376/4885DRD1 3554/4885DRD2 4449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.